Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manel Cascallo

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancer Research|November 1, 2008
Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potencyAlena Gros, Jordi Martínez-Quintanilla, Cristina Puig, et al.
Human Gene Therapy|June 23, 2009
Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targetingNeus Bayo-Puxan, Marta Gimenez-Alejandre, Sergio Lavilla-Alonso, et al.
Scientific Reports|October 9, 2019
The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor modelsMarc Garcia-Moure, Naiara Martinez-Velez, Marisol Gonzalez-Huarriz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2010
Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenovirusesJuan J Rojas, Sonia Guedan, Peter F Searle, et al.
Cancer Research|September 7, 2007
ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivoMarta M Alonso, Manel Cascallo, Candelaria Gomez-Manzano, et al.
Plos One|January 26, 2016
Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01Beatriz Vera, Naiara Martínez-Vélez, Enric Xipell, et al.
Plos One|June 10, 2016
Correction: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01Beatriz Vera, Naiara Martínez-Vélez, Enric Xipell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric OsteosarcomaNaiara Martínez-Vélez, Enric Xipell, Beatriz Vera, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 6, 2021
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11Ana Mato-Berciano, Sara Morgado, María V Maliandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Research|November 1, 2008
Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potencyAlena Gros, Jordi Martínez-Quintanilla, Cristina Puig, et al.
Human Gene Therapy|June 23, 2009
Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targetingNeus Bayo-Puxan, Marta Gimenez-Alejandre, Sergio Lavilla-Alonso, et al.
Scientific Reports|October 9, 2019
The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor modelsMarc Garcia-Moure, Naiara Martinez-Velez, Marisol Gonzalez-Huarriz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2010
Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenovirusesJuan J Rojas, Sonia Guedan, Peter F Searle, et al.
Cancer Research|September 7, 2007
ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivoMarta M Alonso, Manel Cascallo, Candelaria Gomez-Manzano, et al.
Plos One|January 26, 2016
Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01Beatriz Vera, Naiara Martínez-Vélez, Enric Xipell, et al.
Plos One|June 10, 2016
Correction: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01Beatriz Vera, Naiara Martínez-Vélez, Enric Xipell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric OsteosarcomaNaiara Martínez-Vélez, Enric Xipell, Beatriz Vera, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 6, 2021
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11Ana Mato-Berciano, Sara Morgado, María V Maliandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
Pageof 3